Evidence map›Paper›PMID 38229794›Full record

ArticleCureus2023

A Case of JAK2V617F-Negative Myeloproliferative Neoplasm in a Young Female Presenting With Extreme Thrombocytosis.

Kelash Kumar, Assile Koubeissy, Arichanah Pulenthiran, Amrat Kumar, Amit Gulati, Brian Wolf, Stephen Peeke

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kelash KumarDepartment of Internal Medicine, Maimonides Medical Center, Brooklyn, USA.
Assile KoubeissyDepartment of Internal Medicine, Maimonides Medical Center, Brooklyn, USA.
Arichanah PulenthiranDepartment of Internal Medicine, Maimonides Medical Center, Brooklyn, USA.
Amrat KumarDepartment of Internal Medicine, Bassett Medical Center, Cooperstown, USA.
Amit GulatiDepartment of Internal Medicine, Maimonides Medical Center, Brooklyn, USA.
Brian WolfDepartment of Hematology and Oncology, Maimonides Medical Center, Brooklyn, USA.
Stephen PeekeDepartment of Hematology and Oncology, Maimonides Medical Center, Brooklyn, USA.
Maimonides Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombocytosis is a commonly observed condition in clinical practice and typically results from various pathophysiological factors, such as iron deficiency, blood loss, infection, medications, rheumatologic conditions, malignancy, asplenia, post-splenectomy, or familial factors. However, extreme thrombocytosis, defined as a platelet count > 10,000 K/UL (equal or greater than a million), is a rare occurrence. In this report, we present a compelling case of severe thrombocytosis attributed to underlying chronic myelogenous leukemia (CML), further complicated by coexisting iron deficiency. It is essential to emphasize that not all instances of extreme thrombocytosis are indicative of essential thrombocythemia. Hence, maintaining a high level of suspicion for non-ET myeloproliferative neoplasms (MPNs) such as CML, as well as other underlying conditions like iron deficiency anemia, is crucial for accurate diagnosis and timely management.

Indexed as

chronic myeloid leukemia (cml)extreme thrombocytosishydroxyurea usejak inhibitorsplenomegaly

Identifiers

PMID38229794
PMCPMC10791019
OpenAlexW4389856204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.